Missing Information
Missing information in an EU risk management plan (RMP) is not simply a population that was excluded from clinical trials or a situation in which evidence is sparse. It is a gap in knowledge about the safety of a medicinal product that is relevant to its risk-management planning because the safety profile in that population or use situation could differ from what is already known.
That distinction is essential. Every development programme contains unanswered questions, but the RMP should remain focused on gaps that matter to safe use and benefit-risk assessment.
- Missing Information
- Purpose and Regulatory Context
- Missing Information Is a Knowledge Gap, Not an Adverse Event
- Why Absence of Data Is Not Enough
- Sources of Scientific Rationale
- Populations Not Studied in Clinical Trials
- Relationship With Benefit-Risk
- From Knowledge Gap to RMP Classification
- Relationship With the Pharmacovigilance Plan
- Relationship With Risk Minimisation
- Lifecycle Management
- Special Situations
- Practical Implementation
- Governance and QPPV Oversight
- Potential Failure Modes
- Inspection Considerations
- Practical Review Checklist
- Key Takeaways
- References
- Regulatory Note
Purpose and Regulatory Context
EU legislation requires marketing-authorisation applicants and holders to operate a risk-management system, while GVP Module V — Risk management systems explains how the safety specification should identify important identified risks, important potential risks and missing information.
GVP Module V specifically addresses populations not studied in clinical trials. It explains that exclusion from clinical development does not automatically create missing information. A population should be considered as missing information when use is relevant to the approved or proposed indication and there is a scientific rationale to suspect that the safety profile in that population could differ, while available information remains insufficient to determine the safety concern.
The regulatory logic is therefore:
limited or absent information → plausible safety relevance → importance to risk management → missing information.
The first element alone is not enough.
Missing Information Is a Knowledge Gap, Not an Adverse Event
Important identified and potential risks describe adverse clinical outcomes. Missing information describes uncertainty about safety knowledge.
| Safety concern | What is uncertain? |
|---|---|
| Important identified risk | The risk is established; questions may remain about frequency, severity, risk factors or minimisation |
| Important potential risk | A specific adverse outcome is suspected but causality is unconfirmed |
| Missing information | Safety information in a relevant population or use situation is insufficient to determine whether the safety profile differs |
This prevents a common error: classifying “use in pregnancy” itself as a potential risk. Pregnancy may represent missing information when relevant data are insufficient. A specific suspected developmental toxicity outcome, by contrast, would require separate evaluation as a potential or identified risk depending on the evidence.
Why Absence of Data Is Not Enough
Clinical trials exclude many groups for ethical, scientific and practical reasons. A product may therefore have limited data in very elderly people, severe renal impairment, severe hepatic impairment, pregnancy, breastfeeding, immunocompromised patients or people with multiple comorbidities.
Those gaps should not automatically be transferred into the RMP.
The key questions are:
- Is use in this population or situation relevant to the authorised or proposed use?
- Is there a scientific reason to think the safety profile could differ?
- Is the current information insufficient to determine that safety profile?
- Would resolving the uncertainty matter to risk-management planning or safe clinical use?
If the answer to these questions is weak, the item may represent ordinary data limitation rather than RMP-level missing information.
Sources of Scientific Rationale
A knowledge gap becomes more relevant when there is a scientifically credible basis for expecting different safety behaviour.
Examples include:
- altered pharmacokinetics in renal or hepatic impairment;
- different pharmacodynamic sensitivity in children or older adults;
- immunological differences relevant to biologic medicines;
- pregnancy-related physiological changes affecting exposure;
- a plausible transfer into breast milk;
- long latency when authorised use is chronic but trial exposure was short;
- important interactions in a population likely to receive concomitant therapy; or
- disease-specific factors that could modify susceptibility to adverse reactions.
The rationale should be product-specific. A generic statement such as “elderly patients were underrepresented” does not explain why the gap matters.
Populations Not Studied in Clinical Trials
GVP Module V asks the RMP to discuss relevant populations excluded from clinical trials and to consider whether the safety profile might differ.
This section serves two purposes. First, it records important limitations of the development programme. Second, it helps determine whether any of those limitations should become formal missing information in the summary of safety concerns.
The two should not be confused. A population can be described as underrepresented without being designated as missing information.
Relevance to the indication matters
A population that is unlikely to receive the medicine within the authorised conditions may not warrant RMP-level missing information. Conversely, a common real-world population that was sparsely represented in trials may be highly relevant if pharmacology or disease characteristics could alter safety.
The decision should reflect actual or reasonably anticipated use rather than an abstract list of special populations.
Relationship With Benefit-Risk
Missing information matters because uncertainty can affect confidence in the product's benefit-risk balance.
For example, if a medicine is likely to be widely used in severe renal impairment and exposure is expected to rise substantially in that population, insufficient safety data may have direct consequences for dose selection, monitoring and patient selection.
By contrast, a very small evidence gap that is unlikely to change clinical use or risk management may not justify a formal safety concern.
The RMP should therefore explain why the missing knowledge matters, not merely state that the knowledge is missing.
From Knowledge Gap to RMP Classification
A defensible missing-information decision can be built through a sequence of scientific questions rather than numerical triggers.
1. Define the population or use situation precisely
Broad labels such as “elderly,” “pregnancy,” or “long-term use” may be too vague. The RMP should define the actual uncertainty: for example, use in severe renal impairment, exposure during the first trimester, or treatment beyond the duration meaningfully represented in the clinical programme.
2. Describe what is already known
The assessment should summarise the available evidence rather than treating the gap as absolute. This can include clinical-trial exposure, pharmacokinetic data, non-clinical findings, spontaneous reports, observational evidence, class information and published literature.
3. Explain why the safety profile could differ
The scientific rationale is central. A knowledge gap becomes risk-management relevant when there is a credible reason why the excluded or under-studied situation could change exposure, susceptibility, adverse outcomes or the consequences of those outcomes.
4. Explain why the uncertainty matters
The RMP should connect the gap to potential clinical or benefit-risk consequences. Would resolving it affect monitoring, dose selection, contraindications, precautions, treatment choice or confidence in safe use?
5. Determine how the uncertainty should be addressed
The next question is methodological: what evidence can realistically reduce the uncertainty? The answer may be routine pharmacovigilance, an observational study, a registry, targeted follow-up, additional clinical or pharmacokinetic work, or simply continued accumulation of evidence through normal use.
Relationship With the Pharmacovigilance Plan
Missing information does not automatically require an additional post-authorisation study.
GVP Module V links the safety specification to the pharmacovigilance plan, but the activity should follow the scientific question. Additional pharmacovigilance is justified where routine activities cannot adequately address an important uncertainty and where a feasible study can materially improve knowledge.
Examples include:
| Knowledge gap | Possible evidence approach |
|---|---|
| Safety in severe renal impairment | pharmacokinetic/safety study, observational data or targeted clinical collection depending on the product |
| Pregnancy outcomes | structured pregnancy follow-up, registry or observational database study where appropriate |
| Long-term exposure | extension study, registry, longitudinal cohort or real-world data analysis |
| Safety in a paediatric subgroup | planned paediatric development data or post-authorisation observational follow-up |
| Use with a clinically important interacting therapy | targeted clinical, pharmacokinetic or observational evaluation |
No universal exposure count, pregnancy number or person-year threshold determines whether an item qualifies as missing information or when it can be removed. Such thresholds may be designed for a specific study, but they are not generic GVP rules.
Relationship With Risk Minimisation
Missing information is uncertainty rather than a known adverse outcome. Risk minimisation should therefore be proportionate to what is known.
Product information may appropriately state that data are limited or provide precautions where pharmacology and available evidence justify them. Additional risk-minimisation measures, however, should not be created simply because an RMP contains missing information.
The key distinction is whether there is an actual risk requiring minimisation or primarily an uncertainty requiring evidence generation.
Lifecycle Management
Missing information should not remain in the RMP indefinitely merely because the item appeared in the initial marketing-authorisation dossier.
As evidence accumulates, several outcomes are possible.
Retain
The knowledge gap remains clinically relevant and insufficiently resolved. The RMP should describe what has changed since the previous assessment and why focused management remains necessary.
Refine
The original category may prove too broad. For example, “use in renal impairment” may become more precisely limited to severe impairment after data establish the safety profile in mild and moderate impairment.
Remove
An item may be removed when sufficient information becomes available to characterise the safety profile so that the gap no longer requires RMP-level focus, or when the population/use situation is no longer relevant to authorised use.
Reclassify
New evidence may reveal a specific adverse outcome. If a causal association is suspected or established, that outcome should be evaluated under the criteria for an important potential or important identified risk rather than continuing to be represented only as missing information.
Removal or reclassification should reflect the totality of evidence. There is no universal requirement for a fixed number of exposed patients, pregnancies, years of follow-up or a predetermined annual review interval.
Special Situations
Pregnancy and breastfeeding
Pregnancy and breastfeeding are common examples of limited pre-authorisation information, but neither should be included automatically. The decision depends on anticipated use, biological plausibility, available reproductive and clinical evidence, product characteristics and the potential consequences of uncertainty.
Paediatric and older populations
Age alone does not create missing information. The assessment should consider whether age-related pharmacokinetic, pharmacodynamic, disease or treatment factors could alter safety and whether the population is relevant to the authorised indication.
Renal and hepatic impairment
These populations are particularly relevant when organ function materially affects exposure or elimination. The RMP should distinguish between absence of direct clinical data and an actual unresolved safety question supported by pharmacology.
Long-term use
Short clinical-trial exposure may create meaningful uncertainty when the medicine is intended for chronic use and there is a plausible basis for delayed or cumulative toxicity. Again, duration alone is not sufficient; the gap should be connected to a safety rationale.
Biological medicinal products
For biologicals, missing information may sometimes involve long-term immunogenicity, use in immunocompromised populations, pregnancy or switching contexts. The scientific rationale should account for molecular properties, mechanism, immunogenicity and available clinical experience rather than assuming that all biologics require the same RMP categories.
Practical Implementation
A useful operational record for each missing-information item can capture:
- the precisely defined knowledge gap;
- the evidence currently available;
- the scientific rationale for a potentially different safety profile;
- why the gap matters to risk management;
- the evidence-generation strategy, if any;
- important new evidence since the previous RMP; and
- the current retain, refine, remove or reclassify decision.
This is recommended practice, not a prescribed EMA form. Its purpose is to make the lifecycle reasoning reconstructable.
Governance and QPPV Oversight
EU pharmacovigilance requirements establish responsibilities for the marketing-authorisation holder and QPPV, but they do not prescribe a single internal committee structure for every missing-information decision.
In practice, assessment may require pharmacovigilance, clinical development, epidemiology, regulatory affairs, pharmacology and other specialists. Multidisciplinary review can be useful because the decision sits at the boundary between clinical evidence, anticipated use and risk-management planning.
The QPPV should have appropriate visibility of significant changes in the RMP safety specification and the status of important pharmacovigilance activities. That does not mean the QPPV must personally sign every missing-information classification or study milestone.
Potential Failure Modes
The following are illustrative failure modes, not published inspection findings.
| Failure mode | Why it weakens the RMP | Better approach |
|---|---|---|
| Listing every trial-excluded population as missing information | Confuses absence of data with risk-management relevance | Require product-specific scientific and clinical justification |
| Using fixed exposure counts as universal inclusion thresholds | Creates unsupported pseudo-regulatory rules | Use the totality of evidence and the context of intended use |
| Treating pregnancy automatically as missing information | Ignores product characteristics and anticipated exposure | Assess pregnancy-specific relevance and evidence |
| Treating missing information as a potential risk | Confuses uncertainty about a population with a suspected adverse outcome | Separate knowledge gaps from causal risk hypotheses |
| Automatically assigning a PASS or registry | Makes the pharmacovigilance plan activity-driven | Choose studies only when they can answer an important question |
| Keeping the same item indefinitely | Prevents the RMP from becoming more focused as knowledge matures | Reassess whether the gap remains relevant and unresolved |
| Removing an item because an arbitrary numeric target was met | Numbers alone may not answer the safety question | Assess whether the resulting evidence actually characterises safety adequately |
| Requiring a specific committee or QPPV signature for every decision | Converts recommended governance into a pseudo-requirement | Use a governance model proportionate to significance and organisational structure |
Inspection Considerations
An inspector or regulatory reviewer may examine whether missing-information entries reflect a coherent and current scientific rationale rather than a legacy list carried forward from earlier RMP versions.
Relevant questions could include:
- Why is this population or use situation relevant to the authorised medicine?
- What scientific basis suggests that the safety profile could differ?
- What information is already available?
- Why is the remaining uncertainty important to risk management?
- Are pharmacovigilance activities logically connected to the gap?
- What new evidence has accumulated since the previous RMP?
- Why is the item being retained, refined, removed or reclassified?
- Are conclusions consistent with product information, clinical data, PSUR/PBRER evaluations and regulatory commitments?
- Does the QPPV have appropriate awareness of significant RMP changes and unresolved evidence-generation commitments?
The focus is on scientific justification, traceability and lifecycle management, not on whether the company used a particular internal template.
Practical Review Checklist
This checklist is recommended operational practice, not an EU regulatory requirement.
- Is the knowledge gap defined precisely?
- Is the population or use situation relevant to the authorised or proposed indication?
- Is there a scientific basis to suspect a different safety profile?
- Is current information genuinely insufficient to determine that profile?
- Would resolving the uncertainty affect risk management or safe clinical use?
- Is the item correctly distinguished from a potential or identified risk?
- Is the evidence-generation approach proportionate to the question?
- Are routine pharmacovigilance activities sufficient, or is additional evidence generation justified?
- Has important new evidence since the previous RMP been incorporated?
- Is the rationale for retention, refinement, removal or reclassification reconstructable?
- Are product information and related regulatory documents consistent with the current understanding?
- Are internal numerical targets clearly identified as study-specific rather than regulatory thresholds?
Key Takeaways
Missing information is a safety-relevant knowledge gap, not a synonym for limited data. A population excluded from clinical trials should be included as missing information only when the population is relevant to authorised use, there is a scientific rationale to suspect a different safety profile, and available evidence remains insufficient.
The category should remain selective. Pregnancy, older age, renal impairment or long-term use are not automatic entries; each requires product-specific reasoning.
Missing information does not automatically require an additional pharmacovigilance study or additional risk minimisation. The activity should follow the unresolved scientific question.
There are no universal patient-exposure counts, pregnancy numbers, person-year thresholds or annual review intervals that determine inclusion or removal. Lifecycle decisions should depend on whether the evidence now adequately characterises the relevant safety question.
References
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V — Risk management systems (Rev. 2). EMA/838713/2011 Rev. 2.
- European Medicines Agency. Guidance on the format of the risk management plan (RMP) in the EU — integrated format, Rev. 2.0.1. EMA/164014/2018 Rev. 2.0.1.
- European Medicines Agency. Risk management plans (RMP) in post-authorisation phase: questions and answers. EMEA-H-19984/03 Rev. 118, updated 13 July 2026.
- European Union. Commission Implementing Regulation (EU) No 520/2012, consolidated version current at 12 February 2026.
- European Union. Directive 2001/83/EC, as amended.
- European Union. Regulation (EC) No 726/2004, as amended.
- International Council for Harmonisation. ICH E2E Pharmacovigilance Planning.
Regulatory Note
This article distinguishes binding EU requirements, GVP and EMA procedural guidance, scientific interpretation and recommended operational practice. As of 7 September 2026, EMA continues to direct applicants to GVP Module V Rev. 2 and the integrated EU RMP format Rev. 2.0.1, while noting that GVP revisions are planned following Commission Implementing Regulation (EU) 2025/1466. Current guidance should be checked before a live regulatory submission.